Phaseline

Companies › Kyowa Kirin

Kyowa Kirin: clinical trials, targets and expected readouts

10 active drug programs in 11 registered trials: 7 Phase 1, 3 Phase 2, 1 Phase 3; Oncology, Ophthalmology, Metabolic and endocrine, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KK8398
Unclear - code-named drug for achondroplasia
–Phase 3AchondroplasiaMay 2029
KHK4951
Kallikrein-bradykinin pathway inhibitor
KLKB1Phase 2Neovascular Age-Related Macular Degeneration (nAMD); Diabetic Macular Edema (DME)Nov 2026
Zandelisib (ME-401)
PI3-kinase p110-delta subunit inhibitor
PIK3CDPhase 2Indolent B-cell Non-Hodgkin's LymphomaMay 2028
KK2430–Phase 1Hematologic NeoplasmsApr 2027
KK3910–Phase 1Healthy Volunteers Essential HypertensionDec 2027
KK2223–Phase 1T-cell NHL (PTCL or CTCL)Mar 2029
KK2269–Phase 1Advanced Solid TumorMar 2029
KK2260–Phase 1Advanced or Metastatic Solid TumorsOct 2029
KK8123
FGF23 inhibitor
–Phase 1X-linked HypophosphatemiaJun 2030
KK2845–Phase 1Relapsed or Refractory AML and Other Hematologic MalignanciesNov 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06116890KHK4951Phase 2Neovascular Age-Related Macular Degeneration (nAMD)OphthalmologyJun 2026
NCT06116916KHK4951Phase 2Diabetic Macular Edema (DME)OphthalmologyNov 2026
NCT07629726KK2430Phase 1Hematologic NeoplasmsOncologyApr 2027
NCT06823947KK3910Phase 1Healthy Volunteers Essential HypertensionCardiovascularDec 2027
NCT04533581Zandelisib (ME-401)Phase 2Indolent B-cell Non-Hodgkin's LymphomaOncologyMay 2028
NCT07192471KK2223Phase 1T-cell NHL (PTCL or CTCL)OncologyMar 2029
NCT06266299KK2269Phase 1Advanced Solid TumorOncologyMar 2029
NCT06926491KK8398Phase 3AchondroplasiaOtherMay 2029
NCT06248411KK2260Phase 1Advanced or Metastatic Solid TumorsOncologyOct 2029
NCT06525636KK8123Phase 1X-linked HypophosphatemiaMetabolic and endocrineJun 2030
NCT06812104KK2845Phase 1Relapsed or Refractory AML and Other Hematologic MalignanciesOncologyNov 2031

From the company's SEC filings

Complete response letters from FDA

Targets

KLKB1 (1) PIK3CD (1)

Companies with the same targets

KalVista Pharmaceuticals BioCryst Pharmaceuticals ADARx Pharmaceuticals Pharvaris Netherlands DiaMedica Therapeutics Incyte Biosciences Japan GK Pharming Technologies Incyte Rhizen Pharmaceuticals SecuraBio

Companies built like this

Minghui Pharmaceutical (Hangzhou) Abbisko Therapeutics Shandong Boan Biotechnology DualityBio Rhizen Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.